Weight Loss Medications Lead to Notable Muscle Loss Alongside Fat Loss

A study conducted by UNC School of Medicine has found that incretin-based weight loss medications, including semaglutide and tirzepatide, cause significant muscle loss in addition to fat reduction. Both medications are widely prescribed for treating type 2 diabetes and obesity. The research reveals that these drugs are associated with high rates of muscle loss relative to the total amount of weight lost. The findings raise concerns about potential long-term metabolic effects from the muscle loss experienced by patients taking these medications.

Muscle Loss Associated with Incretin-Based Weight Loss Medications

• ▪Incretin-based medications including semaglutide and tirzepatide are associated with high rates of muscle loss relative to the amount of weight lost.
• ▪Semaglutide is widely prescribed for type 2 diabetes and obesity.

Study Findings from UNC School of Medicine

• ▪The UNC School of Medicine study on incretin-based medications found these medications are associated with high rates of muscle loss relative to the amount of weight lost.
• ▪UNC School of Medicine conducted a study of incretin-based medications including semaglutide and tirzepatide.

Implications for Diabetes and Obesity Treatment

• ▪Incretin-based medications are prescribed for type 2 diabetes treatment.

Perspective of UNC School of Medicine researchers

• ▪The rate of muscle loss relative to total weight lost from incretin-based medications is notably high.
• ▪The muscle loss associated with semaglutide and tirzepatide raises concerns about long-term metabolic effects.

1 source